Advertisement

Topics

EQS-News: Polyphor AG: Polyphor enters worldwide exclusive license agreement with Santhera to develop and commercialize POL6014 in cystic fibrosis and other pulmonary diseases

01:40 EST 15 Feb 2018 | FinanzNachrichten

Dow Jones received a payment from EQS/DGAP to publish this press release. EQS Group-News: Polyphor AG / Key word(s): Alliance/Alliance Polyphor AG: Polyphor enters worldwide exclusive license agre...

Original Article: EQS-News: Polyphor AG: Polyphor enters worldwide exclusive license agreement with Santhera to develop and commercialize POL6014 in cystic fibrosis and other pulmonary diseases

NEXT ARTICLE

More From BioPortfolio on "EQS-News: Polyphor AG: Polyphor enters worldwide exclusive license agreement with Santhera to develop and commercialize POL6014 in cystic fibrosis and other pulmonary diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.